Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Delcath Systems Inc (DCTH)

Delcath Systems Inc (DCTH)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 352,034
  • Shares Outstanding, K 31,974
  • Annual Sales, $ 2,070 K
  • Annual Income, $ -47,680 K
  • EBIT $ -27 M
  • EBITDA $ -26 M
  • 60-Month Beta 0.85
  • Price/Sales 170.48
  • Price/Cash Flow N/A
  • Price/Book 35.69

Options Overview Details

View History
  • Implied Volatility 71.54% ( -0.69%)
  • Historical Volatility 67.14%
  • IV Percentile 36%
  • IV Rank 41.35%
  • IV High 171.42% on 03/06/24
  • IV Low 1.11% on 08/16/24
  • Put/Call Vol Ratio 0.29
  • Today's Volume 112
  • Volume Avg (30-Day) 304
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 5,666
  • Open Int (30-Day) 7,496

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.10
  • Number of Estimates 1
  • High Estimate -0.10
  • Low Estimate -0.10
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +79.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
9.76 +17.21%
on 11/25/24
13.30 -13.99%
on 12/16/24
+1.68 (+17.21%)
since 11/22/24
3-Month
8.08 +41.58%
on 10/10/24
13.30 -13.99%
on 12/16/24
+2.70 (+30.89%)
since 09/23/24
52-Week
3.70 +209.19%
on 03/14/24
13.30 -13.99%
on 12/16/24
+7.43 (+185.29%)
since 12/22/23

Most Recent Stories

More News
News Movers: Today’s Hottest News That Could Move the Needle Tomorrow

WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...

BCLI : 2.07 (-9.21%)
LASE : 5.49 (-0.18%)
PPBT : 3.70 (+8.19%)
BCTX : 0.5290 (-5.70%)
STXS : 2.35 (unch)
DCTH : 11.44 (+3.91%)
DMGGF : 0.2591 (-5.47%)
Delcath Systems Announces a Comparative Study of Chemosat and SIRT Published in the Journal Cancers

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 11.44 (+3.91%)
Delcath Systems to Participate in the Lytham Partners Fall 2023 Investor Conference

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 11.44 (+3.91%)
Delcath Systems to Participate at the Roth MKM 2023 Healthcare Opportunities Conference on October 12, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 11.44 (+3.91%)
Delcath Systems Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and...

DCTH : 11.44 (+3.91%)
A Retrospective Comparative Study of Chemosat and SIRT Presented at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Annual Meeting

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 11.44 (+3.91%)
Delcath Systems to Participate at the H.C. Wainwright 25th Annual Investor Conference on September 12 and 13, 2023

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 11.44 (+3.91%)
Delcath Systems, Inc. Announces Additional $35 Million in Funding Tied to the FDA Approval of HEPZATO KITâ„¢

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 11.44 (+3.91%)
Stock Index Futures Plunge on Pressure from Rising Bond Yields, China Data Disappoints

September S&P 500 futures (ESU23) are down -0.61%, and September Nasdaq 100 E-Mini futures (NQU23) are down -0.48% this morning as market participants digested the latest U.K. employment data, which fueled...

ESU23 : 4,491.72s (-0.32%)
NQU23 : 15,435.20s (-0.28%)
NVDA : 139.67 (+3.69%)
X : 31.37 (+4.08%)
MNDY : 231.85 (-4.39%)
TSLA : 430.60 (+2.27%)
KEY : 17.22 (+0.76%)
CMA : 61.86 (+1.14%)
HD : 392.45 (-0.04%)
SU : 35.03 (+1.54%)
ALC : 85.38 (+0.73%)
A : 134.60 (+0.07%)
Delcath Systems, Inc. Announces FDA Approval of HEPZATO KITâ„¢ for the Treatment of Adult Patients with Unresectable Hepatic-Dominant Metastatic Uveal Melanoma

/PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the...

DCTH : 11.44 (+3.91%)

Business Summary

Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic agents directly to the liver.

See More

Key Turning Points

3rd Resistance Point 12.48
2nd Resistance Point 11.99
1st Resistance Point 11.72
Last Price 11.44
1st Support Level 10.96
2nd Support Level 10.47
3rd Support Level 10.20

See More

52-Week High 13.30
Last Price 11.44
Fibonacci 61.8% 9.63
Fibonacci 50% 8.50
Fibonacci 38.2% 7.37
52-Week Low 3.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar